famotidine has been researched along with Osteoporosis in 1 studies
Famotidine: A competitive histamine H2-receptor antagonist. Its main pharmacodynamic effect is the inhibition of gastric secretion.
Osteoporosis: Reduction of bone mass without alteration in the composition of bone, leading to fractures. Primary osteoporosis can be of two major types: postmenopausal osteoporosis (OSTEOPOROSIS, POSTMENOPAUSAL) and age-related or senile osteoporosis.
| Excerpt | Relevance | Reference |
|---|---|---|
| " This study was undertaken to determine whether patients with chronic use of H2-receptor antagonists (HRA) had demonstrable decreases in bone mineral density (BMD)." | 1.30 | Bone mineral density in patients taking H2-receptor antagonist. ( Adachi, Y; Iso, Y; Kitano, S; Matsumata, T; Shiota, E; Yoh, R, 1998) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Adachi, Y | 1 |
| Shiota, E | 1 |
| Matsumata, T | 1 |
| Iso, Y | 1 |
| Yoh, R | 1 |
| Kitano, S | 1 |
1 other study available for famotidine and Osteoporosis
| Article | Year |
|---|---|
Bone mineral density in patients taking H2-receptor antagonist.
Topics: Adult; Aged; Bone Density; Case-Control Studies; Cimetidine; Duodenal Ulcer; Famotidine; Female; His | 1998 |